BRUSSELS, Belgium — Where coverage with evidence development (CED) programs are well-established, though applied sparingly, in North America such early market access schemes for medical devices are new to Europe. And characteristic of the fragmented regulatory landscape found here, the approaches and requirements vary greatly among 30-plus countries.
Read More
